ACAD ACADIA Pharmaceuticals Inc.
$20.17▲ +2.18%
Healthcare
Other
After hours
$20.17▲ +0.00%
Oct 27, 4:41 PM ET
Volume 1.33M
Avg Volume (10D) 1.51M
Key Metrics & Fundamentals
Market Cap
$3.48B
P/E Ratio
9.0
Div Yield
0.00%
52W Range
18.39 - 30.96
% vs 50 MA
-16.98%
% vs 200 MA
-15.15%
RSI-14
41.0
MACD Histogram
+0.3500
Beta (1Y vs SPY)
0.69
Free Cash Flow
$95.69M
Gross Rev
$307.96M
Gross Profit
$279.64M
EBITDA
$40.99M
COGS
$28.32M
Operating Exp
$241.81M
Operating Income
$37.84M
EBIT
$37.84M
Pretax Income
$46.47M
Net Income
$31.50M
EPS (Diluted)
0.18
Price & Volume History
Loading chart…
Recent News
Acadia Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 4, 2026
Business Wire · Oct 21, 2026 4:05 PM ET
Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3?
Zacks · Oct 21, 2026 10:00 AM ET
ACADIA Pharmaceuticals Shares Fall After UBS Downgrade
MT Newswires · Oct 13, 2026 2:55 PM ET
Top Midday Decliners
MT Newswires · Oct 13, 2026 2:01 PM ET
Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects?
Zacks · Oct 13, 2026 9:01 AM ET
UBS Downgrades ACADIA Pharmaceuticals to Neutral From Buy, $23 Price Target
MT Newswires · Oct 13, 2026 7:19 AM ET
4 CNS Drug Stocks Worth Watching This World Mental Health Day
Zacks · Oct 9, 2026 9:28 AM ET
RBC Trims Price Target on ACADIA Pharmaceuticals to $36 From $37, Keeps Outperform Rating
MT Newswires · Oct 8, 2026 7:03 AM ET
Acadia Pharmaceuticals (ACAD) Secures Patent And Phase 2 Progress, Is It 38% Below Fair Value?
Simply Wall St. · Oct 5, 2026 9:07 PM ET
Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041
Zacks · Sep 29, 2026 9:06 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See ACAD's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.